CG Oncology Ratios (2023-2025) | CGON

Ratios Mar2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
Gross Margin 5.34%
EBT Margin -4,471.65%-130,666.67%-1,655,100.00%-3,199.43%-17,036.04%-47,448.84%-6,974.56%-66,263.46%-2,623.53%
EBIT Margin -5,010.82%-156,033.33%-1,935,500.00%-4,247.45%-23,290.99%-65,802.33%-8,344.08%-81,161.54%-3,068.97%
EBITDA Margin -5,010.82%-156,033.33%-1,935,500.00%-4,247.45%-23,290.99%-65,802.33%-8,344.08%-81,161.54%-3,068.97%
Operating Margin -5,010.82%-156,033.33%-1,935,500.00%-4,247.45%-23,290.99%-65,802.33%-8,344.08%-81,161.54%-3,068.97%
Net Margin -6,392.27%-194,600.00%-2,249,000.00%-3,200.76%-17,028.83%-47,453.49%-6,973.25%-66,263.46%-2,623.53%
FCF Margin -4,116.49%-136,244.44%-1,464,500.00%-4,919.47%-14,535.14%-37,018.60%-4,576.97%-56,376.92%-2,340.40%
Efficiency
Assets Average 389.20M571.72M558.40M653.63M741.49M714.81M715.68M
Equity Average 222.92M560.65M544.56M635.07M719.07M687.56M679.00M
Invested Capital -123.10M568.94M552.36M536.77M733.38M704.76M670.36M687.64M
Asset Utilization Ratio 0.000.000.000.000.000.00
Leverage & Solvency
Debt to Equity 0.00
Debt Ratio 0.00
Equity Ratio -0.620.980.980.970.970.970.960.94
Valuation
Enterprise Value -187.67M2,358.82M1,550.95M1,990.11M1,197.62M1,178.12M1,320.81M2,390.99M
Market Capitalization 2,925.33M2,103.83M2,530.82M1,939.62M1,866.55M1,981.86M3,071.25M
Return Ratios
Return on Sales -77.48%-98.69%-106.42%-77.30%-159.48%-68.29%
Return on Capital Employed -0.18%-0.15%-0.18%-0.18%-0.19%-0.23%-0.26%
Return on Assets -0.15%-0.11%-0.13%-0.13%-0.14%-0.18%-0.21%
Return on Equity -0.25%-0.11%-0.13%-0.14%-0.15%-0.19%-0.22%